Take Our PhysQuiz on ACR Convergence 2020!

1) DMARD-naïve patients achieving Routine Assessment of Patient Index Data 3 (RAPID3) and the Clinical Disease Activity for Psoriatic Arthritis (cDAPSA) targets with apremilast (Otezla), showing early and sustained improvements after how long?*

a) 52 weeks
b) 32 weeks
c) 24 weeks
d) 16 weeks

2) In a study presented at ACR 2020, family history of psoriasis (odds ratio [OR] = 2.71, 95% confidence interval [CI] 1.24 – 5.90) and psoriasis severity (OR=1.96, 95% CI 1.26 -3.06) were more likely in those who had a delay in transition from psoriasis to PsA than those who had a concomitant diagnosis.*

a) True
b) False

3) 1) Data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2 showed that guselkumab (Tremfya) improved what in adult patients with active psoriatic arthritis (PsA) and maintained response through 52 weeks of active treatment?*

a) Swollen joints
b) Bone density
c) Fatigue
d) PsA disease activity

4) What drug is the first and only FDA-approved selective anti-IL-23 therapy for active psoriatic arthritis and the only therapy for psoriatic arthritis to have improvement in fatigue as measured by FACIT-F in the product label?*

a) Ixekizumab
b) Deucravacitinib (Talz)
c) Guselkumab (Tremfya)
d) None of the above

CAPTCHA

Follow Us

Take Our PhysQuiz on ACR Convergence 2020!

Author